In other subgroups of NSCLC, PD-L1 expression in tumour cells is significantly lower, e.g., in adenocarcinoma (25.0%, 5/20), squamous carcinoma (15.8%, 3/19), or large cell carcinoma (20.0%, 3/15) [21]. This evidence concerns the gene CD274 and adenocarcinoma.